What follows is a plain explanation of what the La protein does, how laboratories report this test, what a positive and a negative result each leave open, and which questions are worth taking to a clinician.
La, also called SSB, is a protein that sits mainly in the cell nucleus and binds newly made RNA transcripts, acting as a chaperone while those transcripts are processed and handed on. It is a normal, useful part of ordinary cell biology, present in everybody's cells.
An autoantibody is an antibody the immune system makes against one of the body's own molecules rather than against a virus or a bacterium. Anti-La/SSB belongs to a family of autoantibodies directed at extractable nuclear antigens, the group most labs run as an ENA panel. Anti-La/SSB is associated with Sjögren's syndrome and with lupus erythematosus 1. Sjögren's syndrome is a chronic autoimmune condition in which immune cells infiltrate the moisture-producing glands, so dryness of the eyes and mouth is its defining feature 2.
Why tolerance to a normal self protein breaks down in some people and not others is not settled, and no blood test answers that question. What the test does answer is narrower and still useful. A detectable antibody means the immune system has mounted a sustained, organised response against that specific nuclear protein, which is not something that happens in passing. It does not tell you how much gland tissue is affected, how someone feels, or how things will change over time.
That distinction matters for reading your own result calmly. The antibody is a signal about immune behaviour. The diagnosis, if there is one, comes from the whole picture, symptoms, examination findings, other laboratory results and sometimes tissue sampling, interpreted by a clinician.
They target different proteins and they do not carry equal weight in clinical assessment. Anti-SSA/Ro is directed at the Ro proteins, usually reported as Ro52 and Ro60, and it can appear on its own. Anti-SSB/La is directed at the La protein and, in practice, is almost always found in company with anti-SSA/Ro rather than by itself.
| Feature | Anti-SSA (Ro) | Anti-SSB (La) |
|---|---|---|
| Target antigen | Ro52 and Ro60 nuclear and cytoplasmic proteins | La/SSB RNA-binding phosphoprotein |
| Usual pattern | Can be positive alone | Usually positive together with anti-SSA |
| Place in formal classification | Anti-SSA/Ro positivity is a weighted item in the 2016 ACR/EULAR classification criteria for primary Sjögren's syndrome 3 | Not scored as a separate item in those criteria |
| Other settings it appears in | Lupus erythematosus and Sjögren's syndrome 1 | Lupus erythematosus and Sjögren's syndrome 1 |
Research suggests that anti-Ro/SSA and anti-La/SSB antibodies occur together in Sjögren's syndrome considerably more often than anti-La appears alone 4. That pairing is why the two are nearly always ordered as a couple, and why an isolated anti-La result with no anti-Ro is usually looked at twice, sometimes by repeating the sample or using a different assay method.
The practical consequence is simple. Anti-SSA/Ro does most of the diagnostic work in the formal criteria, while anti-SSB/La adds context about the breadth of the antibody response. Neither one, on its own, decides anything.
Because a pattern of symptoms has raised the question of an autoimmune cause, and this test narrows the field. The usual triggers are persistent dry eyes and dry mouth that do not settle, swelling of the salivary glands in front of the ear or under the jaw, fatigue that is out of proportion to activity, and aching or swollen joints. Dryness of the eyes and mouth is the defining feature of Sjögren's syndrome, which is a chronic autoimmune condition of the exocrine glands 2.
A second common route is an incidental finding. Someone has a positive antinuclear antibody (ANA) test done for another reason, and the laboratory or the clinician follows it with an ENA panel to see which specific nuclear target, if any, the antibodies are aimed at. Anti-SSA and anti-SSB are two of the specificities that panel looks for.
A third route is systemic. Evidence suggests that primary Sjögren's syndrome can involve features beyond the glands, including joints, skin, lungs, kidneys and nerves 5. So the test is sometimes requested when an unexplained systemic picture needs sorting out, not only when the complaint is dryness.
What the test is not useful for is screening a person with no symptoms and no clinical question. Ordering antibody tests at random produces borderline results that are hard to interpret and easy to worry about. The order should follow a question.
There is no single universal numeric reference range for this antibody, because results are assay-dependent. Most laboratories report anti-SSB/La qualitatively as negative, equivocal or positive, often with a semi-quantitative number in arbitrary units such as U/mL or an antibody index, judged against that assay's own cut-off.
| Result category | How laboratories typically report it | What it tells you |
|---|---|---|
| Negative | Below the assay cut-off | No detectable anti-La/SSB antibody in that sample using that method |
| Equivocal or borderline | At or very close to the cut-off | Unclear. Laboratories often suggest a repeat sample or a second method |
| Positive | Above the cut-off, usually with a numeric value in arbitrary units | Detectable antibody, to be read with symptoms, examination and other markers |
These are typical laboratory reporting categories, not fixed biological thresholds. Cut-offs, units and methods vary between laboratories and assay platforms, and reference ranges in general vary by lab, age and sex, so a number from one laboratory should not be compared directly with a number from another.
Read a result in three steps. The observation is whether the antibody was detectable and how far above the cut-off it sat. The meaning is that an immune response against the La protein is present, which narrows the possible explanations for a symptom pattern without naming one. The next step is to bring the report, with the method and cut-off printed on it, to the clinician who ordered it, so the result is interpreted against your examination rather than against the internet.
It suggests that the immune system is producing antibodies against the La protein, and it moves an autoimmune explanation up the list of possibilities without confirming any single one. The 2016 ACR/EULAR classification criteria for primary Sjögren's syndrome combine anti-SSA/Ro positivity with items such as labial salivary gland biopsy findings, ocular staining score, Schirmer testing and unstimulated salivary flow 3. An antibody result is one input into that kind of structured assessment, not a substitute for it.
Autoantibodies, including anti-Ro/SSA and anti-La/SSB, are the laboratory biomarkers most used in the assessment of Sjögren's syndrome 6. At the same time, anti-Ro/SSA and anti-La/SSB antibodies are found in lupus erythematosus as well as in Sjögren's syndrome 1, so a positive result does not point to only one destination.
The honest summary for a reader holding a positive report is this. Something real has been detected. The detection is specific enough to be informative and non-specific enough that it cannot stand alone. A rheumatologist or the ordering clinician decides what, if anything, follows, and any treatment decision is made by a licensed provider after reviewing the whole person.
Yes. A negative anti-SSA and anti-SSB pair does not close the question in someone with persistent dryness. Studies indicate that people with Sjögren's disease who are negative for both anti-SSA and anti-SSB antibodies show a distinguishable clinical and immune profile compared with those who are antibody positive 7.
That is why the formal assessment does not rest on serology alone. The 2016 criteria include objective measures of dryness and glandular inflammation, such as ocular staining, Schirmer testing, unstimulated whole salivary flow and labial salivary gland biopsy, alongside anti-SSA/Ro status 3. A person can score through those routes without a positive antibody.
There are also mundane explanations for persistent dryness that have nothing to do with autoimmunity, from environmental and occupational exposure to the effects of other medical conditions, and a clinician is the right person to work through them. The practical point for a reader with a negative result and ongoing symptoms is not to treat the negative as a dismissal. Symptoms that persist deserve a second conversation, and sometimes a different kind of assessment rather than a repeat of the same blood test.
Several things, which is why interpretation is never automatic. The most common alternative context is another systemic autoimmune condition, since these antibodies appear in lupus erythematosus as well as in Sjögren's syndrome 1.
Low-level positive results can also turn up in people with few or no relevant symptoms. An assay cut-off is a statistical boundary, so results just above it carry less certainty than results far above it, and a borderline value is often repeated rather than acted on.
Method differences matter too. Different platforms use different antigen preparations and different cut-offs, so the same serum can read borderline on one assay and clearly positive on another. If you have results from two laboratories that seem to disagree, check whether the method and units on the two reports are even the same before concluding that something has changed.
Finally, there is the question that results cannot answer. A positive antibody does not tell you when the immune response began, how fast anything is progressing, or what symptoms will develop. Treating one printed value as a forecast is the most common misreading of this test, and the correction is to bring it back to a clinician who can place it next to your examination.
It is a standard venous blood draw, usually a single tube, with no fasting required for the antibody test itself. The sample is sent to a laboratory that runs an immunoassay against the La antigen and reports the result against its own cut-off.
Two practical points are worth knowing. First, anti-SSB/La is rarely ordered in isolation. It generally comes as part of an ENA panel with anti-SSA/Ro and other nuclear specificities, often after an ANA result, so the report you receive may list several antibodies at once. Second, it is often drawn in the same sitting as general blood work, and some of those other tests do require fasting. Follow the instruction given for the whole requisition rather than for this one test.
Turnaround time depends on whether the laboratory runs the panel in-house or sends it out, so ask the collecting site rather than assuming a date. There is no special timing within the day, no need to avoid exercise beforehand, and nothing in an ordinary meal that changes an autoantibody result.
When the report arrives, keep the full document rather than the headline word. The method, the units and the cut-off printed alongside the number are what make the result interpretable later, particularly if testing is ever repeated at a different laboratory.
The ones that build context around the antibody rather than duplicate it. Autoantibodies are the laboratory biomarkers most used in assessing Sjögren's syndrome, and interest continues in markers that add information beyond them 6.
In practice, a clinician investigating this picture commonly looks at several groups of tests together.
None of these confirms or excludes an autoimmune diagnosis on its own. Their value is in pattern. A broad panel repeated over time shows which values move together, which stay put, and which deserve a closer look. FitScript's membership covers 150+ biomarkers tested per year, with interpretation by Atlas, its AI health advisor, and any treatment decision made by a licensed provider who has reviewed the member.
ESR is a non-specific marker of systemic inflammation that is often drawn alongside autoantibody testing, because it describes how much inflammatory activity is present rather than what is causing it. Typical lab reference ranges run from 0 to 20 mm/hr, around 0 to 22 mm/hr for men and 0 to 29 mm/hr for women. FitScript's optimal range is 0 to 10 mm/hr, and 0 to 15 mm/hr in women. Those optimal figures are FitScript's optimization targets, not diagnostic cut-offs, and reference ranges vary by lab, age and sex. The dedicated ESR guide covers how the test works and how to read a single value in detail.
Lowering an autoantibody number is not a target a reader should set independently, and it is not what clinical management is organised around. The antibody is a marker of immune activity. What clinicians follow is the person, meaning symptoms, glandular function, organ involvement and quality of life, with laboratory results read as supporting information.
This trips people up because other antibody tests are discussed differently in popular writing. Thyroid autoantibodies, for example, are often framed as a number to push down, which encourages the idea that every autoantibody works the same way. They do not. The clinical weight of an antibody, how it is monitored and whether its level changes anything depend on the specific antibody and the specific condition.
What is reasonable to do is everything that belongs to general health and to good symptom reporting. Keep a clear record of what your symptoms are, when they worsen and what interferes with daily function, and bring that record to appointments. Follow the monitoring schedule your clinician sets. Ask what would prompt a change in assessment.
What is not reasonable is self-directed intervention aimed at a number on a report. Decisions about any therapy for an autoimmune condition belong to a licensed provider who evaluates whether it is appropriate for the individual in front of them.
That is a clinician's decision, and it usually depends on how clear the first result was. A borderline or equivocal value is commonly repeated, sometimes on a different assay, because the uncertainty sits in the measurement rather than in the person. A clearly positive result is a different matter, since repeating a test that has already answered its question adds cost without adding information.
Where follow-up testing does earn its place is in the surrounding markers rather than in the antibody itself. Blood counts, inflammation markers, kidney and liver function and organ-specific assessments change over time in a way that an established antibody status often does not, and those are the numbers that tend to guide monitoring intervals.
If you move laboratories, expect the format of the report to change. Units, cut-offs and even the way the result is worded differ between platforms, so a visually different number does not necessarily mean a biologically different situation. Bring the older report with you so the two can be compared on method as well as on value.
For most people, immediately after the result, it means better observation rather than a different life. The useful work is noticing and recording what your body does, because that record is what turns a single antibody result into a usable clinical picture.
Worth tracking and reporting are persistent dryness of the eyes or mouth and how it affects reading, speaking, eating or sleeping, any swelling of the salivary glands, fatigue patterns, joint pain and stiffness, skin changes, breathlessness, and any new numbness or tingling. Evidence suggests that primary Sjögren's syndrome can involve organ systems beyond the glands, including joints, lungs, kidneys and the nervous system 5, which is why symptoms that seem unrelated to dryness are still worth mentioning.
It is also sensible to ask your clinician what routine eye and dental review they recommend for your situation and how often, rather than waiting for a problem to force the question. Dryness has downstream consequences for ocular surface comfort and dental health, and the schedule should be set by the people looking after those areas.
Finally, keep expectations proportionate. A positive antibody in someone with mild symptoms and a normal examination is a different situation from the same antibody in someone with marked dryness and systemic features. The report does not distinguish between the two. Your clinician does.
When symptoms change quickly or involve an organ rather than only comfort. Eye pain, light sensitivity or any change in vision warrants prompt attention. So does new or rapidly increasing salivary gland swelling, particularly if it is firm, one-sided or persistent. New breathlessness, chest pain, significant unexplained weight loss, new numbness or weakness, or a new rash with fever are all worth discussing with a clinician promptly rather than at the next routine appointment.
A result that is simply outside the standard range is a different category. It is suboptimal information rather than an emergency, and the right response is a scheduled conversation with the clinician who ordered it, with the full report in hand. Never ignore an abnormal result, and never conclude from one value that you do or do not have a condition.
This page is educational and is not medical advice. Discuss your results and any treatment with a clinician or licensed provider who can assess your full history.
If you are mapping the inflammatory picture around an antibody result, the guide to c reactive protein explains the other marker most often drawn alongside a sedimentation rate, and the article on how to lower tpo antibodies is a useful contrast for understanding why different autoantibodies are monitored in different ways.
It measures whether your blood contains antibodies directed at the La protein, a normal protein found in the nucleus of your cells. Labs run it as part of an ENA panel, almost always together with the SSA (Ro) antibody test. The result tells you whether that specific immune response is detectable, not what caused it.
No. A positive result makes an autoimmune explanation more likely for a given set of symptoms, but it does not name a condition on its own. These antibodies appear in more than one autoimmune condition, and a clinician reaches any diagnosis using your history, examination and other tests together.
It is uncommon. The two antibodies usually travel together, so an isolated SSB positive result with a negative SSA is often rechecked, sometimes on a different assay or with a fresh sample. Your clinician decides whether a repeat is worthwhile.
Not for this antibody test itself. It is a standard blood draw with no special preparation. If other tests are being collected at the same time, follow the fasting instruction given for the whole requisition rather than for this single test.
It means that antibody was not detectable in that sample with that method, and nothing more. Persistent dryness still deserves assessment, and there are objective ways to measure tear production, eye surface changes and saliva flow that do not depend on antibody status. Book a follow-up rather than treating the negative as the end of the matter.
That is a decision for the clinician who ordered it. Borderline results are commonly repeated because the uncertainty lies in the measurement, while a clearly positive result often does not need redoing. Ongoing monitoring usually focuses on symptoms and on other blood tests rather than on re-running the same antibody.
ANA is a broad screen that detects antibodies against nuclear material in general, without saying which target they are aimed at. SSA and SSB testing is the next step down, identifying specific nuclear targets. A positive ANA is often what prompts the more specific panel.
Bring the full laboratory report, not just the word positive, because the method, units and cut-off printed on it matter for interpretation. Bring any earlier reports from other labs for comparison. A written log of your symptoms, when they started and how they affect daily life is often the most useful thing you can hand over.